<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Iran. J. Public Health</journal-id><journal-id journal-id-type="publisher-id">IJPH</journal-id><journal-id journal-id-type="pmc">IJPH</journal-id><journal-title-group><journal-title>Iranian Journal of Public Health</journal-title></journal-title-group><issn pub-type="ppub">2251-6085</issn><issn pub-type="epub">2251-6093</issn><publisher><publisher-name>Tehran University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6277710</article-id><article-id pub-id-type="publisher-id">ijph-47-1575</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Estimation of Economic Burden of Hepatitis C Virus Infection in Iran</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>MOHAMMADZADEH</surname><given-names>Mehdi</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>DERAFSHI</surname><given-names>Hamid</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref><xref ref-type="aff" rid="AFF4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>GHARI</surname><given-names>Tayebeh</given-names></name><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref><xref ref-type="aff" rid="AFF5"><sup>5</sup></xref><xref ref-type="corresp" rid="C1"><sup>*</sup></xref></contrib><aff id="AFF1"><label>1.</label>Dept. of Pharmacoeconomy and Administrative Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><aff id="AFF2"><label>2.</label>Pharmacoeconomy &#x00026; Medical-Pharma Management Research Center, Tehran, Iran</aff><aff id="AFF3"><label>3.</label>Dept. of Ophthalmology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran</aff><aff id="AFF4"><label>4.</label>Dept. of Ophthalmology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran</aff><aff id="AFF5"><label>5.</label>Dept. of Pharmaceutics, School of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran</aff></contrib-group><author-notes><corresp id="C1"><label>*</label><bold>Corresponding Author:</bold> Email: <email>tayebehghari@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2018</year></pub-date><volume>47</volume><issue>10</issue><fpage>1575</fpage><lpage>1582</lpage><history><date date-type="received"><day>09</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>12</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>Copyright&#x000a9; Iranian Public Health Association &#x00026; Tehran University of Medical Sciences</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>One of the major causes of liver-related mortality and morbidity is Hepatitis C Virus (HCV) infection. It is also one of the reasons behinds of chronic liver disease and related complications such as cirrhosis and hepatocellular carcinoma. This autoimmune liver disease imposes a high economic burden on individuals and the society. This study aimed to estimate burden of HCV in Iran.</p></sec><sec><title>Methods:</title><p>Overall, 200 patients with HCV infection, referred to hospitals in three cities of Tehran, Karaj and Tabriz, Iran during year 2015, were randomly enrolled. To estimate the total burden of hepatitis, direct and indirect costs, costs of DALYs and social welfare were calculated.</p></sec><sec><title>Results:</title><p>Economic burden of HCV infection was obtained 26242.8 purchasing power parity (PPP$). Intangible costs of HCV was calculated 207421.6 PPP$.</p></sec><sec><title>Conclusion:</title><p>Total direct costs of HCV for each patient are more than household consumption expenditure. Therefore, it is a reasonable policy to control and increase insurance coverage of HCV patients in order to decrease their costs.</p></sec></abstract><kwd-group><kwd>Hepatitis C</kwd><kwd>Economic burden of disease</kwd><kwd>Direct and indirect costs</kwd><kwd>DALYs</kwd><kwd>Iran</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>One of the major causes of liver-related mortality and morbidity is Hepatitis C Virus (HCV) infection. It is also one of the reasons behinds of chronic liver disease and related complications such as cirrhosis and hepatocellular carcinoma (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Overall, 350,000 global deaths in a year have occurred because of HCV-related complications (<xref rid="B3" ref-type="bibr">3</xref>). HCV considered as an important disease in both developed and developing countries (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). There are 160 million patients with HCV infection in the worldwide (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Transmission of this blood-borne pathogen will occur due to the exposure to the contaminated body fluids and blood (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>). Despite our knowledge about hepatitis C virology and pathogenesis has been grown rapidly, there is little information about the current and future burden of this infection throughout the world. It may potentially need considerable health care services and impose very high costs for health systems in the United States, Europe, and others. Therefore, it is essential to have the information about hepatitis burden in order to the development of national and international health policies for prevention of complications and control of disease and injury (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>Several methods have been proposed to quantify population-level burden of disease. The disability-adjusted life years (DALYs) is one way to measure population health which is being increasingly used in comparing and analyzing the burden due to diseases (<xref rid="B10" ref-type="bibr">10</xref>). It is a concept similar to healthy year includes weights for time spent in less-than-perfect health. DALYs are formed from two components: years of life lost (LLY) because of premature death and years lived with disability (YLD) consist of nonfatal injuries and disease (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>). To measure the economic burden of hepatitis, a considerable number of studies have been published in the literature. The global epidemiology and burden of hepatitis C were measured. The total burden related to HCV may be as high as 4.2 million DALYs (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>The average diagnosis and treatment costs of hepatitis C were studied. One course of treatment and six months after that with standard protocol plus Ribavirin and Peg-interferon plus Ribavirin have costs of exceeds 3,850 and 16,494 purchasing power parity dollars (PPP$) respectively (<xref rid="B13" ref-type="bibr">13</xref>). Hepatitis C is a very important and expensive disease for health care system. HCV patients need expensive drug treatments and require high health care services (<xref rid="B13" ref-type="bibr">13</xref>). A modeling approach was used to quantify the current HCV-infected population, future disease progression and associated costs in Egypt. With newer therapies, strategies to reduce disease burden are feasible and cost-effective (<xref rid="B14" ref-type="bibr">14</xref>). In one study, future morbidity, mortality, and costs resulting from HCV have been estimated. Number of deaths for chronic liver disease and hepatocellular carcinoma were estimated 165900 and 27200 deaths during year 2010 until year 2019 respectively. Indirect medical costs for HCV services were calculated $10.7 billion. From 2010 until 2019, HCV cause the loss of 1.83 million years of life in people younger than 65 with cost of $21.3 and $54.2 billion, respectively (<xref rid="B15" ref-type="bibr">15</xref>). In another study, cost-effectiveness of generic direct-acting antivirals (DAAs) for hepatitis C treatment was evaluated. By use of DAAs, the life expectancy increased by 8.02 years and the lifetime healthcare costs by $1,309 per-person treated in comparison of no treatment (<xref rid="B16" ref-type="bibr">16</xref>). To the best of our knowledge, the disability-adjusted life year&#x02019;s estimation has not been done on HCV infection in Iran.</p><p>We aimed to estimate the population-level burden of HCV infection by calculating the disability-adjusted life years, direct and indirect costs and social welfare.</p></sec><sec sec-type="methods"><title>Methods</title><p>Our study was descriptive, analytical, applied and retrospective. To do this study, 200 patients with HCV infection, who referred to hospitals in three cities of Tehran, Karaj and Tabriz, Iran during year 2015, were randomly selected.</p><p>Written informed consent was obtained from each participant. The study was approved by Ethics Committee of Shahid Beheshti University of Medical Sciences, Tehran, Iran.</p><p>Public library system and questionnaire were used for data collections. Questionnaire which contains information about demographic and patient&#x02019;s history, quality of life, work productivity and activity impairment was prepared. Content validity of the questionnaire was examined with reference to the gastroenterologists&#x02019; and pharmacoeconomists&#x02019; comments and opinions. They were asked to evaluate relevance, completeness, scoring and clarity of each question. The Cronbach&#x02019;s Alpha Coefficient for each question was determined to test the reliability of the questionnaire. Cronbach&#x02019;s Alpha Coefficient more than 0.75 was approved level to each question. Correlation of each question with other questions was higher than medium level and there was no negative correlation (an inverse relationship) between questions.</p><p>After questionnaire preparation, a review of the literature was undertaken to recognize the latest treatments available for patients with HCV, in Iran. In order to calculate total economic burden of hepatitis C, the algebraic sum of direct medical costs, direct non-medical costs and indirect costs was obtained. Costs of DALYs and costs of economic welfare index were also calculated as intangible costs. These items were collected as following:</p><p>For direct medical and non-medical costs and indirect costs&#x02019; calculations, diagnostic and laboratory tests, physician visits and drug treatments were considered as direct medical costs and transportation, meals and telephone conversation were considered as direct non-medical costs. Common therapeutic protocol in HCV infection including direct-acting antivirals (DAAs) was used (<xref rid="B6" ref-type="bibr">6</xref>). We also calculated accommodation costs as direct non-medical costs. As most of patients were in their own cities and did not need accommodation. Therefore we eliminated accommodation costs from total non-medical direct costs. Days of absence from work (patient or his/her caregiver) were calculated as indirect costs by use of Laspeyres index.</p><p>The unit costs of these items (diagnostic and laboratory tests and physician visits) were calculated (<ext-link ext-link-type="uri" xlink:href="http://irmna.com/">http://irmna.com/</ext-link>). The prices of medication were retrieved from drug list of Food and Drug Organization of Iran (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov.ir/en/">http://www.fda.gov.ir/en/</ext-link>).</p><p>To estimate the total burden of hepatitis, we also calculated DALYs (disability-adjusted life years) using Murray methodology (<xref rid="B17" ref-type="bibr">17</xref>). The years of life lost (YLL) because of premature mortality and the years lived with disability (YLD) are the two components of DALYs. Life expectancy was considered 74 and 77 year for men and women respectively based on life expectancy in Iran. Incidence, duration, and disability weight are the information specifically required for calculating YLD. For estimation of parts of economic burden based on calculated DALYs, we multiplied DALYs by GDP (gross domestic product) per capita. 15572.83 PPP$. PPP$ was used for the purpose of international comparisons. We also added economic welfare index for calculating the total economic burden of hepatitis. Welfare index was calculated by social welfare cardinal function as below:
<disp-formula><mml:math id="m1"><mml:mrow><mml:mi>W</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>n</mml:mi></mml:mfrac><mml:munderover><mml:mo>&#x02211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>&#x000af;</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Where W is social welfare, Y<sub>i</sub> is the income of individual and n is number of individuals. Finally, total economic burden of hepatitis C was obtained by the algebraic sum of direct medical costs, direct non-medical costs and indirect costs. Costs of DALYs and costs of economic welfare index were also calculated as intangible costs.</p></sec><sec sec-type="results"><title>Results</title><sec sec-type="subjects"><title>Characterizations of patients with HCV infection</title><p>The study was done on 200 patients with HCV infection in Iran. The demographic characteristics of the mentioned patients have been shown in <xref rid="T1" ref-type="table">Table 1</xref>. Mean age (&#x000b1; standard deviation) of patients with HCV infection in our study was 35.5 &#x000b1; 6.4. 165 patients (82.5 %) were male and majority of patients (132 (66%)) were married.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1:</label><caption><p>Socio-economic characterizations of patients with HCV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>Variables</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Frequency</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Relative frequency (%)</italic></bold></th></tr></thead><tbody><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Gender</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">165</td><td align="center" valign="top" rowspan="1" colspan="1">82.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">35</td><td align="center" valign="top" rowspan="1" colspan="1">17.5</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Age group(yr)</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">20&#x02013;30</td><td align="center" valign="top" rowspan="1" colspan="1">14</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">31&#x02013;40</td><td align="center" valign="top" rowspan="1" colspan="1">80</td><td align="center" valign="top" rowspan="1" colspan="1">40</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">41&#x02013;50</td><td align="center" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">51&#x02013;60</td><td align="center" valign="top" rowspan="1" colspan="1">55</td><td align="center" valign="top" rowspan="1" colspan="1">27.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e; 61</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">3.5</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Marital status</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Single</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">34</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Married</td><td align="center" valign="top" rowspan="1" colspan="1">132</td><td align="center" valign="top" rowspan="1" colspan="1">66</td></tr></tbody></table></table-wrap><p>In <xref rid="T2" ref-type="table">Table 2</xref>, number of patients based on smoking, drinking, use of drugs and physical activities has been shown. Majority of patients (189 (94.5%), 147 (73.5%)) had no history of drinking and physical activities respectively; however, majority of patients (59.5%) had history of use of drugs.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2:</label><caption><p>Smoking, drinking, use of drugs, physical activity, education and occupational status of HCV patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>Variables</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Frequency</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Relative frequency (%)</italic></bold></th></tr></thead><tbody><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Smoking</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">106</td><td align="center" valign="top" rowspan="1" colspan="1">53</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">94</td><td align="center" valign="top" rowspan="1" colspan="1">47</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Drinking</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">5.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">189</td><td align="center" valign="top" rowspan="1" colspan="1">94.5</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Use of drugs</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">119</td><td align="center" valign="top" rowspan="1" colspan="1">59.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">81</td><td align="center" valign="top" rowspan="1" colspan="1">40.5</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Physical activities</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" rowspan="1" colspan="1">53</td><td align="center" valign="top" rowspan="1" colspan="1">26.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">No</td><td align="center" valign="top" rowspan="1" colspan="1">147</td><td align="center" valign="top" rowspan="1" colspan="1">73.5</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Occupation</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Employed</td><td align="center" valign="top" rowspan="1" colspan="1">137</td><td align="center" valign="top" rowspan="1" colspan="1">68.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unemployed</td><td align="center" valign="top" rowspan="1" colspan="1">63</td><td align="center" valign="top" rowspan="1" colspan="1">31.5</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Education</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Academic</td><td align="center" valign="top" rowspan="1" colspan="1">53</td><td align="center" valign="top" rowspan="1" colspan="1">26.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non academic</td><td align="center" valign="top" rowspan="1" colspan="1">147</td><td align="center" valign="top" rowspan="1" colspan="1">73.5</td></tr></tbody></table></table-wrap><p>We have also evaluated HCV patients in terms of underlying diseases. Liver disease and dementia disease were the most prevalent underlying diseases with frequency of 120 (60 %) and 62 (31%) respectively. Education and occupational status of HCV patients have been displayed in <xref rid="T2" ref-type="table">Table 2</xref>. Most patients were employed but did not have an academic education.</p></sec><sec><title>Direct medical and non-medical costs</title><p>For estimation of direct medical and non-medical costs of HCV infection, we calculated costs of laboratory and diagnostic tests, physician visits and drug treatments as direct medical costs and transportation, meals and telephone conversation as direct non-medical costs.</p><p>Common laboratory and diagnostic tests and their costs have been shown in <xref rid="T3" ref-type="table">Table 3</xref>. Total costs for tests was estimated about 900.9 $ equal to 2945.9 PPP$.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3:</label><caption><p>Common laboratory and diagnostic tests and their costs for patients with HCV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>Laboratory and diagnostic test name</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Unit price ($)</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Frequency of test per year</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Total costs per year ($)</italic></bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Viral load</td><td align="center" valign="top" rowspan="1" colspan="1">89</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">178</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PCR</td><td align="center" valign="top" rowspan="1" colspan="1">138</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">552</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti HCV</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver biopsy</td><td align="center" valign="top" rowspan="1" colspan="1">86.2</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">86.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver sonography</td><td align="center" valign="top" rowspan="1" colspan="1">11.5</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">11.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALT</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">9.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AST</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">9.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALP</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">9.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UA-UC</td><td align="center" valign="top" rowspan="1" colspan="1">3.7</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">14.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bilirubin</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">11.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine</td><td align="center" valign="top" rowspan="1" colspan="1">2.3</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">9.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total costs</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><bold>900.9</bold></td></tr></tbody></table></table-wrap><p>Associated costs for treatment have been presented in <xref rid="T4" ref-type="table">Table 4</xref>. Average drug treatment costs were 6368.3 $ equal to 20824.34 PPP$.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4:</label><caption><p>Common therapeutic protocol in HCV infection and its associated costs for treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>Treatment</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Unit price ($)</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Number of drug per year</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Annual costs ($)</italic></bold></th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1">Treatment one</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sofosbuvir Tablet</td><td align="center" valign="top" rowspan="1" colspan="1">13.6</td><td align="center" valign="top" rowspan="1" colspan="1">365</td><td align="center" valign="top" rowspan="1" colspan="1">4964</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ribavirin Tablet</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">2190</td><td align="center" valign="top" rowspan="1" colspan="1">372.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PEG Interferon alfa 2a</td><td align="center" valign="top" rowspan="1" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1">48</td><td align="center" valign="top" rowspan="1" colspan="1">2064</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><bold>7400.3</bold></td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Treatment two</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sofosbuvir Tablet</td><td align="center" valign="top" rowspan="1" colspan="1">13.6</td><td align="center" valign="top" rowspan="1" colspan="1">365</td><td align="center" valign="top" rowspan="1" colspan="1">4964</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ribavirin Tablet</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td><td align="center" valign="top" rowspan="1" colspan="1">2190</td><td align="center" valign="top" rowspan="1" colspan="1">372.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"><bold>5336.3</bold></td></tr></tbody></table></table-wrap><p><xref rid="T5" ref-type="table">Table 5</xref> shows the annual direct costs of HCV. The total direct costs for HCV infection were 7399.9 $ equal to 24197.6 PPP$ annually. Minimum direct costs for HCV infection was costs of telephone conversation (47.1 PPP$) that it was 0.2% of total direct costs. The most expensive direct costs were also for drug treatment (20824.3 PPP$).</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5:</label><caption><p>Average annual direct medical and non-medical costs per patients with HCV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>Type of costs</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Unit price ($)</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Unit price PPP$</italic></bold></th><th align="center" valign="middle" rowspan="1" colspan="1"><bold><italic>Percentage</italic></bold></th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>Direct medical costs</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Laboratory and diagnostic test</td><td align="center" valign="top" rowspan="1" colspan="1">900.8</td><td align="center" valign="top" rowspan="1" colspan="1">2945.6</td><td align="center" valign="top" rowspan="1" colspan="1">12.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Physician visits</td><td align="center" valign="top" rowspan="1" colspan="1">34.5</td><td align="center" valign="top" rowspan="1" colspan="1">112.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drug treatments</td><td align="center" valign="top" rowspan="1" colspan="1">6368.3</td><td align="center" valign="top" rowspan="1" colspan="1">20824.3</td><td align="center" valign="top" rowspan="1" colspan="1">86</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1"><bold>Direct non-medical costs</bold></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Transportation</td><td align="center" valign="top" rowspan="1" colspan="1">64.7</td><td align="center" valign="top" rowspan="1" colspan="1">211.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Meals</td><td align="center" valign="top" rowspan="1" colspan="1">17.2</td><td align="center" valign="top" rowspan="1" colspan="1">56.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Telephone conversation</td><td align="center" valign="top" rowspan="1" colspan="1">14.4</td><td align="center" valign="top" rowspan="1" colspan="1">47.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>Total</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>7399.9</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>24197.6</bold></td><td align="center" valign="top" rowspan="1" colspan="1"><bold>100</bold></td></tr></tbody></table></table-wrap></sec><sec><title>Indirect costs</title><p>Average indirect costs, ratio of direct to indirect costs and total costs of HCV infection were estimated in <xref rid="T6" ref-type="table">Table 6</xref>. Finally, total costs of direct and indirect costs of HCV infection were obtained 26242.8 PPP$.</p><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6:</label><caption><p>Average indirect costs, ratio of direct to indirect costs and total costs of HCV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"><bold><italic>Type of costs</italic></bold></th><th align="left" valign="top" rowspan="1" colspan="1"><bold><italic>Unit price ($)</italic></bold></th><th align="left" valign="top" rowspan="1" colspan="1"><bold><italic>Unit price (PPP$)</italic></bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Indirect medical costs</td><td align="left" valign="top" rowspan="1" colspan="1">625</td><td align="left" valign="top" rowspan="1" colspan="1">2045.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ratio of direct to indirect costs</td><td align="left" valign="top" rowspan="1" colspan="1">11.8</td><td align="left" valign="top" rowspan="1" colspan="1">11.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total costs of direct and indirect costs</td><td align="left" valign="top" rowspan="1" colspan="1">8025.3</td><td align="left" valign="top" rowspan="1" colspan="1">26242.8</td></tr></tbody></table></table-wrap></sec><sec><title>DALYs (disability-adjusted life years)</title><p>DALYs are formed from years of life lost (LLY) because of premature death and years lived with disability (YLD) consist of nonfatal injuries and disease. In order to calculate the years of life lost (YLL) because of premature mortality, 150 patients passed away because of HCV were randomly selected and their age at death was determined. YLL was obtained 0.87 yr based on the differences between life expectancy and the average age at death in HCV patients.</p><p>Another dimension of the DALY is the time period in years lived in states of poor health or disability due to each disease (YLD). The disability is measured in length in years and in severity. The disability severity weights have been appointed by WHO for each disabling condition on a scale from one to zero. The mentioned scale, patients&#x02019; physical conditions, and experts&#x02019; opinions determine the weights. HCV patients&#x02019; physical conditions and reasons for their disability were evaluated. Reasons of patients&#x02019; disability were determined as insomnia, physical weakness, nervousness, depression, anxiety, joint and muscle pains, loss of appetite, inability to climb stairs, inability to flex knee, inability to walk more than 2 km and breathing problems. Average of severity weight for patients with HCV was obtained 0.34. HCV patients lived 15 yr in health states less than ideal health (with disability). YLD was calculated as follow:
<disp-formula><mml:math id="m2"><mml:mrow><mml:mtext>YLD</mml:mtext><mml:mo>=</mml:mo><mml:mtext>Average</mml:mtext><mml:mo>&#x02009;</mml:mo><mml:mtext>of</mml:mtext><mml:mo>&#x02009;</mml:mo><mml:mtext>severity</mml:mtext><mml:mo>&#x02009;</mml:mo><mml:mtext>weight</mml:mtext><mml:mo>&#x02009;</mml:mo><mml:mo>&#x000d7;</mml:mo><mml:mo>&#x02009;</mml:mo><mml:mtext>years</mml:mtext><mml:mo>&#x02009;</mml:mo><mml:mtext>lived</mml:mtext><mml:mo>&#x02009;</mml:mo><mml:mtext>with</mml:mtext><mml:mo>&#x02009;</mml:mo><mml:mtext>disability</mml:mtext><mml:mo>=</mml:mo><mml:mn>0.34</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mn>11</mml:mn><mml:mo>=</mml:mo><mml:mn>3.74</mml:mn></mml:mrow></mml:math></disp-formula></p><p>YLL and YLD were obtained about 0.8 and 3.74 yr respectively. Finally, DALYs formed from two components was obtained 4.6 yr. Costs of DALYs were gained from GDP per capita by means of YLL and YLD estimation. In <xref rid="T7" ref-type="table">Table 7</xref>, average costs of YLL, YLD, and DALY for each patient has been shown.</p><table-wrap id="T7" orientation="portrait" position="float"><label>Table 7:</label><caption><p>Average costs of LLY and DLY of HCV infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>Type of costs</italic></bold></th><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>Unit price ($)</italic></bold></th><th align="left" valign="middle" rowspan="1" colspan="1"><bold><italic>Unit price (PPP$)</italic></bold></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Costs of YLL</td><td align="left" valign="top" rowspan="1" colspan="1">4167.04</td><td align="left" valign="top" rowspan="1" colspan="1">13626.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Costs of YLD</td><td align="left" valign="top" rowspan="1" colspan="1">17811.1</td><td align="left" valign="top" rowspan="1" colspan="1">58242.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total costs of YLL and YLD (DALYs)</td><td align="left" valign="top" rowspan="1" colspan="1">21938.2</td><td align="left" valign="top" rowspan="1" colspan="1">71868.6</td></tr></tbody></table></table-wrap></sec><sec><title>Social Welfare index</title><p>A cardinal social welfare function is a function that takes as input numeric representations of individual utilities and returns as output a numeric representation of the collective welfare. Costs of social welfare were 135553.1 PPP$.</p><p>Finally, economic burden of HCV infection was gained by sum of direct costs and indirect costs. It was obtained 8025.3 $ equal to 26242.8 PPP$. Intangible costs of HCV were sum of costs of DALYs and costs of social welfare. It was calculated 63431.7 $ equal to 207421.6 PPP$.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>HCV is one of the most common causes of morbidity, mortality and liver transplantation in the future. It also imposes a high socioeconomic burden on patients and the society (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Therefore, calculation of total costs of HCV is useful for healthcare systems to make a suitable health policy in the country. The aim of this study was to obtain total burden of HCV in Iran. Total direct medical and non-medical costs of HCV infection were estimated 24197.6 PPP$ annually per patient. Regarding the HCV patients population in Iran in 2015 (<xref rid="B19" ref-type="bibr">19</xref>), total direct costs for all HCV population in Iran have obtained 7,259,280,000 PPP$ annually from which the drug treatment costs had the largest share of it. These results are similar to the previous studies regarding high costs of drug treatments in HCV patients (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). Although the prevalence of HCV infection in Iran is low, total direct costs of HCV population are dramatic which means that it has a high priority for our healthcare systems.</p><p>Some portions of direct medical costs of HCV will be decreased due to insurance coverage. According to the insurance coverage percentages, different behavior of the insurance organizations in Iran, share of paid by patients and portion of services covered by insurance, we estimate that up to 40% of direct medical costs will be paid by insurance and the remaining will be deducted from the household consumption expenditure. Therefore, about 4,393,356,000 PPP$ will be imposed on HCV patients population in Iran. As the total health costs in Iran in 2015 was 90,799,249,123 PPP$ (<ext-link ext-link-type="uri" xlink:href="https://data.worldbank.org/">https://data.worldbank.org/</ext-link>), total direct costs of HCV population was equal to 4.8% of it. Since the household consumption expenditure per capita in 2015 was about 9962 PPP$ based on our results, total direct costs of HCV for each patient are more than the household consumption expenditure per capita. Therefore, for the HCV patient, household&#x02019;s income is not enough to cover the costs of it. Another point is about indirect costs of HCV. It will impose 613,560,000 PPP$ on community and health care systems which is due to loss of productivity and can damage the economics of the society. Most of direct costs of HCV were spent on drug treatments. Therefore, it is a reasonable policy of our healthcare systems to increase insurance coverage of HCV drugs in order to decrease costs imposed on HCV patients.</p><p>One of the main measure indexes of disease frequency is incidence. As it is just based on patient&#x02019;s number and basic population data, for comparing between different areas or different times, it must be standardized. Since DALYs consider both survival time and life quality, it is more inclusive than incidence (<xref rid="B22" ref-type="bibr">22</xref>). In addition, in the calculation of DALYs, standardization issues have been considered essentially. Therefore, it can be compared to areas or diseases directly (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). Our results showed that the average DALYs was calculated 4.6 yr. According to the total HCV population in Iran, total DALYs for population was obtained 1,380,000 yr lost from which about 262,500 yr of it was years lost due to premature mortality. Equivalent to 262,500 yr will be deducted from life expectancy in the community.</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>Total direct costs of HCV for each patient are more than household consumption expenditure and for the HCV patient, household&#x02019;s income is not enough to cover the costs of this disease. Therefore, it is a reasonable policy of our health care systems to implement an effective control plan and increase insurance coverage of HCV drugs in order to decrease costs imposed on HCV patients or making a plan to have a more supportive program to cover their costs.</p></sec><sec><title>Ethical considerations</title><p>Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study had no support or funding to report.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Conflict of interest</bold></p><p>The authors declare that there is no conflict of interests.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauer</surname><given-names>GM</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name></person-group> (<year>2001</year>). <article-title>Hepatitis C virus infection</article-title>. <source>N Engl J Med</source>, <volume>345</volume>:<fpage>41</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">11439948</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Organization WH</collab></person-group> (accessed April 2014). <article-title>Guidelines for the screening, care, and treatment of persons with hepatitis C infection</article-title>. <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf">http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf</ext-link></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>SM</given-names></name><name><surname>Wu</surname><given-names>GY</given-names></name></person-group> (<year>2016</year>). <article-title>Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy</article-title>. <source>J Clin Transl Hepatol</source>, <volume>4</volume>:<fpage>310</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">28097100</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alavian</surname><given-names>S</given-names></name></person-group> (<year>2011</year>). <article-title>New globally faces of hepatitis B and C in the world</article-title>. <source>Gastroenterol Hepatol Bed Bench</source>, <volume>4</volume>:<fpage>171</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">24834179</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalantari</surname><given-names>H</given-names></name><name><surname>Jalali</surname><given-names>M</given-names></name></person-group> (<year>2003</year>). <article-title>Ten-year study of histological variations of liver and laboratory findings in 100 healthy hepatitis B Carriers</article-title>. <source>J Isfahan Med Sch</source>, <volume>67</volume>: <fpage>32</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for Study of Liver</collab></person-group> (<year>2015</year>). <article-title>EASL Recommendations on Treatment of Hepatitis C 2015</article-title>. <source>J Hepatol</source>, <volume>63</volume>:<fpage>199</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">25911336</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alter</surname><given-names>M</given-names></name></person-group> (<year>2007</year>). <article-title>Epidemiology of hepatitis C virus infection</article-title>. <source>World J Gastroenterol</source>, <volume>13</volume>:<fpage>2436</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">17552026</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WR</given-names></name></person-group> (<year>2002</year>). <article-title>Global epidemiology and burden of hepatitis C</article-title>. <source>Microbes Infect</source>, <volume>4</volume>:<fpage>1219</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">12467763</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>A</given-names></name></person-group> (<year>1999</year>). <article-title>Calculating the global burden of disease: time for a strategic reappraisal?</article-title>
<source>Health Econ</source>, <volume>8</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10082139</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>C</given-names></name><name><surname>Lopez</surname><given-names>A</given-names></name></person-group> (<year>1996</year>). <source>The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020</source>. ed. <publisher-loc>Cambridge MA</publisher-loc>: <publisher-name>Harvard University Press</publisher-name></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Acharya</surname><given-names>AK</given-names></name></person-group> (<year>1997</year>). <article-title>Understanding DALYs (disability-adjusted life years)</article-title>. <source>J Health Econ</source>, <volume>16</volume>:<fpage>703</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">10176780</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>C</given-names></name><name><surname>Salomon</surname><given-names>J</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name></person-group> (<year>2002</year>). <article-title>A critical examination of summary measures of population health</article-title>. <italic>In:</italic>
<source>Summary measures of population health: concepts, ethics, measurement, and applications</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>. ed.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashtari</surname><given-names>S</given-names></name><name><surname>Vahedi</surname><given-names>M</given-names></name><name><surname>Pourhoseingholi</surname><given-names>MA</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Estimation of average diagnosis and treatment costs of hepatitis C</article-title>. <source>Gastroenterol Hepatol Bed Bench</source>, <volume>5</volume>:<fpage>139</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">24834215</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estes</surname><given-names>C</given-names></name><name><surname>Abdel-Kareem</surname><given-names>M</given-names></name><name><surname>Abdel-Razek</surname><given-names>W</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies</article-title>. <source>Aliment Pharmacol Ther</source>, <volume>42</volume>:<fpage>696</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">26202593</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>McQuillan</surname><given-names>GM</given-names></name><name><surname>McHutchison</surname><given-names>JG</given-names></name><name><surname>Poynard</surname><given-names>T</given-names></name></person-group> (<year>2000</year>). <article-title>Estimating future hepatitis C morbidity, mortality, and costs in the United States</article-title>. <source>Am J Public Health</source>, <volume>90</volume>:<fpage>1562</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11029989</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India</article-title>. <source>PLoS One</source>, <volume>12</volume>:<fpage>e0176503</fpage>.<pub-id pub-id-type="pmid">28520728</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJ</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name></person-group> (<year>1994</year>). <article-title>Quantifying disability: data, methods and results</article-title>. <source>Bull World Health Organ</source>, <volume>72</volume>: <fpage>481</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">8062403</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanwal</surname><given-names>F</given-names></name><name><surname>Farid</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis</article-title>. <source>Am J Gastroenterol</source>, <volume>101</volume>:<fpage>2076</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="pmid">16968510</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W</given-names></name></person-group> (<year>1997</year>). <article-title>Hepatitis B virus infection</article-title>. <source>N Engl J Med</source>, <volume>337</volume>:<fpage>1733</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">9392700</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Touzet</surname><given-names>S</given-names></name><name><surname>Kraemer</surname><given-names>L</given-names></name><name><surname>Colin</surname><given-names>C</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Epidemiology of hepatitis C virus infection seven European Union countries: a critical analysis of a litreature. HENCORE Group. Hepatitis C European Network for Cooperative Resarch</article-title>. <source>Eur J Gastroenterol Hepatol</source>, <volume>12</volume>:<fpage>667</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">10912488</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyles</surname><given-names>DL</given-names></name></person-group> (<year>2010</year>). <article-title>Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection</article-title>. <source>Top HIV Med</source>, <volume>18</volume>:<fpage>132</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">21107012</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>A</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Ezzati</surname><given-names>M</given-names></name><name><surname>Jamison</surname><given-names>D</given-names></name></person-group> (<year>2006</year>). <source>Global burden of disease and risk factors</source>. <publisher-loc>Washington</publisher-loc>: <publisher-name>Oxford University Press and the World Bank</publisher-name>.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaunt</surname><given-names>ER</given-names></name><name><surname>Harvala</surname><given-names>H</given-names></name><name><surname>McIntyre</surname><given-names>C</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Disease burden of the most commonly detected respiratory viruses in hospitalized patients calculated using the disability adjusted life year (DALY) model</article-title>. <source>J Clin Virol</source>, <volume>52</volume>:<fpage>215</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">21880543</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathers</surname><given-names>CD</given-names></name><name><surname>Vos</surname><given-names>ET</given-names></name><name><surname>Stevenson</surname><given-names>CE</given-names></name><name><surname>Begg</surname><given-names>SJ</given-names></name></person-group> (<year>2001</year>). <article-title>The burden of disease and injury in Australia</article-title>. <source>Bull World Health Organ</source>
<volume>79</volume>:<fpage>1076</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">11731817</pub-id></mixed-citation></ref></ref-list></back></article>